GlassScriptPhysician profile
Elisa Hilburn
NPI 1194113399
$2,666.06
in general payments reported to CMS, 2019-2025
21 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $409 · 2023: $899 · 2024: $817 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $801.57 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $555.07 | 2022-2025 | |
| Amgen INC. | $277.20 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $207.97 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $154.83 | 2021-2022 | |
| Boston Scientific Corporation | $103.68 | 2021-2025 | Resonate El Icd Vr |
| Merck Sharp & Dohme LLC | $89.22 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $58.96 | 2024-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $54.17 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $52.81 | 2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $48.65 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $44.98 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $37.09 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $33.80 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $33.54 | 2024 | Amvuttra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.80 | 2024 | Keveyis |
| Pfizer INC. | $20.17 | 2023 | |
| Atricure, INC. | $19.30 | 2023 | |
| Irhythm Technologies, INC. | $18.95 | 2024 | Zio Xt Patch, Zio Monitor |
| Amarin Pharma, INC. | $16.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.36 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Hilburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.